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ABSTRACT 
Objective:  The current classification criteria for idiopathic inflammatory myopathy (IIM) retain 
polymyositis (PM) as a major disease subgroup. However, evolution in the understanding of IIM 
has suggested that many of these patients could be better described as having an alternative 
diagnosis. In the present study, we apply the latest understanding of IIM subtyping to 
retrospectively review PM diagnoses in a large cohort of IIM patients. 
Methods: Within a previously reported cohort of 255 patients from a UK tertiary myositis clinic, 
37 patients classified as PM according to both the EULAR/ACR IIM criteria and expert opinion 
were identified. Clinical data and complementary tests were reviewed, and consensus decisions 
regarding final classification were reached in each case.  
Results: Nine (9/37, 24.3%) patients remained classified as PM, 3.5% (9/255) of the original 
cohort; these PM patients were seronegative for myositis antibodies, responsive to 
immunosuppression, and in 4/7 (57.1%) patients where muscle biopsy was performed had HLA-
1 upregulation and endomysial inflammatory infiltrates. Immune-mediated necrotizing 
myopathy (5/37, 13.5%) and connective tissue disease overlap myositis (7/37, 19%) were the 
main alternative diagnoses. The remaining patients were diagnosed as: unspecified myopathy 
(6/37, 16%), dermatomyositis (2/37, 5%), cancer-associated myopathy (3/37, 8.1%), and non-
inflammatory myopathy (1/37, 3%, myofibrillar myopathy). Four patients (4/37, 10%) had 
insufficient data available to confidently reclassify.  
Conclusion: Our study confirms that PM can now be considered a rare IIM subgroup.  A thorough 
examination, complete myositis autoantibody panel, and careful interpretation of the biopsy 
results is recommended to confirm the correct IIM sub-type. 
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- Classification criteria for inflammatory myopathies do not currently include subgroups 
that are considered relevant. 
- Polymyositis is rare and should be only considered after other disease subgroups are 
excluded. 
- Immune-mediated necrotizing myopathy or connective tissue disease-overlap myositis 





















Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune 
connective tissue diseases characterised by skeletal muscle inflammation and weakness, often 
accompanied by involvement of other systems including the skin, lung, or joints. The 
identification of specific IIM sub-types allows clinicians to predict prognosis, make individualised 
treatment plans, and facilitate development of targeted therapeutic approaches. 
The understanding of polymyositis (PM) has evolved substantially since the Bohan and Peter 
criteria were published in 1975(1,2). An expanded variety of IIM subgroups are now recognised, 
defined according to clinical features, histopathological findings, and the presence of myositis-
specific (MSA) or myositis-associated autoantibodies (MAA). Patients historically labelled with 
PM may now be considered to have an alternative IIM clinical sub-type, including immune-
mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASS), connective tissue-
disease-overlap myositis (CTD-OM), cancer-associated myositis (CAM), or inclusion body 
myositis (IBM)(3).  
There are several proposed criteria to distinguish the IIM sub-types, but are mainly empirically 
derived and not fully validated(4–8). In contrast, the recent EULAR/ACR classification criteria for 
IIM were developed and validated using robust procedures(9). Nevertheless, limitations remain, 
notably the retention of PM as a major diagnostic category and the inability to distinguish IIM 
subgroups such as IMNM or ASS. Consequently, diagnostic subgroups used in clinical practice 
are increasingly diverging from those which we are able to apply using the published 
criteria(10,11).  
Parker et al previously described the performance of the EULAR/ACR criteria in our “real world” 
IIM cohort and examined agreement with expert opinion(10). In summary, 255 patients with 
definite or probable IIM by EULAR/ACR criteria were identified. 124 patients were classified as 
PM according to these criteria, but among those patients only 37 (39.8%) were classified as PM 
according to expert opinion, given that classification criteria fail to correctly diagnose some 
patients(12). Given the ongoing uncertainties regarding the existence of PM as a diagnostic 
subgroup of IIM, we undertook a detailed review of these 37 cases seeking to understand the 




MATERIALS AND METHODS 
Case identification and classification 
We re-analysed data regarding a previously described cohort of adult-onset IIM cases from 
Salford Royal NHS Foundation Trust (SRFT), UK, focussing on those classified as PM(10). From a 
total of 255 IIM cases, 37 patients were identified as PM by both EULAR/ACR criteria (probable 
or definite) and expert opinion. Records were reviewed to confirm clinical characteristics, 
autoantibody (Ab) profile, electromyography (EMG), muscle magnetic resonance imaging (MRI), 
and muscle biopsy findings. Information about administered treatments and outcomes was also 
examined.  
As this is a “real world” cohort, not all patients had every investigation performed. However, in 
most cases, antibodies were detected using the Euroimmun myositis line blot (Euroline 
Autoimmune Inflammatory Myopathies, Lübeck, Germany), which includes anti-Mi2, anti-Tif1 
gamma, anti-MDA5, anti-NXP2, anti-SAE1, anti-Ku, anti-Pm-Scl, anti-Jo1, anti-PL7, anti-PL12, 
anti-EJ, anti-OJ, anti-SRP and anti-Ro-52. In addition, some patients had immunoprecipitation 
performed and testing for HMGCR Abs by ELISA. Antinuclear antibodies (ANA) were detected by 
indirect immunofluorescence on Hep-2 cells. ANA positivity included those with cytoplasmic and 
nuclear staining. 
Each case was then classified as one of the following: PM, DM, IMNM, CTD-OM, IBM, CAM, ASS, 
non-inflammatory myopathy, unspecified myopathy and “incomplete data”. This decision was 
made by consensus of expert opinion (HC, JBL, JLM). As part of this process, existing 
diagnostic/classification criteria for each subgroup were applied where available, noting that 
each of these patients had already been defined as an IIM case using the EULAR/ACR criteria. 
IBM was diagnosed if the patient was classified as clinico-pathologically defined or clinically 
defined IBM by 2013 ENMC criteria(4), IMNM was diagnosed according to 2018 ENMC proposed 
criteria(5), CTD-OM was diagnosed according to Troyanov criteria(8) and ASS was diagnosed 
either by Connor criteria(6) or Solomon Criteria(7). DM was diagnosed according to the presence 
of typical skin rash and/or presence of DM-specific abs (Mi-2, Tif1 gamma, MDA5, NXP2, SAE1). 
CAM was diagnosed if the patient developed a malignancy within 3 years of myositis diagnosis. 
Finally, PM was defined as symmetrical muscle weakness, without skin involvement and with 
clear response to immunosuppressive therapy (where data was available) in those that they did 
not fulfil other subgroup criteria.  
For patients not meeting these criteria, the following labels were applied: ‘Non-inflammatory 
myopathy’ was defined as a confirmed diagnosis or strong clinical suspicion of non-inflammatory 
myopathy such as limb-girdle muscle disease (LGMD), dystrophinopathy or myofibrillar 
myopathy made during follow-up; ‘Unspecified myopathy’ was diagnosed where consensus 
could not classify the case into one of the stated sub-groups, despite the availability of all 
relevant clinical information and investigation results; ‘Undeterminate due to incomplete data’ 
was used only where there was insufficient data to classify the patient due to important 
outstanding investigation results or clinical information.  
This study was performed as part of a quality improvement project evaluating the 
neuromuscular service at SRFT. Case notes and other data were reviewed retrospectively 
without alteration to patient management.  Given this context, and after consultation with the 
Health Research Authority (via www.hra-decisiontools.org.uk), this study proceeded without 
further requirement for ethical authorization. 
 
Statistical methods 
Statistical analyses were performed using SPSS version 22. Categorical numbers were presented 





Thirty-seven patients with PM according to EULAR/ACR IIM criteria and by expert opinion were 
included in the analysis. Twenty-six patients (26/37, 68.4%) were female. The mean age at 
diagnosis was 57 years (SD 16.25) and mean follow up was 5.2 years (SD 4.8). 
After consensus discussions, nine patients (9/37, 24.3%) retained classification as PM, 
representing 3.5% (9/255) of the original cohort of 255 patients. The remaining 27 were 
reclassified as follows: CTD-OM (7/37, 18.9%), IMNM (5/37, 13.5%), CAM (3/37, 8.1%) 
unspecified myopathy (6/37, 16.2%), DM (2/37, 5.4%), and non-inflammatory myopathy (1/37, 
2.7%, myofibrillar myopathy). Four patients (4/37, 10%) had insufficient data available to allow 
for a defined diagnosis. 
 
The restricted modern entity of PM 
Of the 9 patients retaining classification as PM, 6 (66.6%) were female, and mean age at 
diagnosis was 58.11 years (SD 13.69). Clinical characteristics are represented in Table 1. Mean 
CK at diagnosis was 2446.9IU/L (SD 2204). Regarding autoantibody testing, 9 patients (100%) 
were tested for the complete myositis autoantibody panel and 3 (33.3%) were specifically tested 
for the presence of HMGCR antibodies and found to be negative (table 2). EMG revealed a 
myopathic pattern in 5/6 (83.3%) patients tested. Muscle MRI was performed in 5 cases, which 
showed muscle oedema in a pattern compatible with active myositis in 3/5 (60%). None of these 
9 patients had prior exposure to statins or other myotoxins. 
A complete muscle biopsy report was available in 7/9 PM-classified patients (77.7%); diffuse 
HLA-1 upregulation was present in 4/7 patients (57.1%), endomysial inflammatory infiltrates in 
4/7 (57.1%) and perimysial infiltrates in 3/7 (42.8%) (in conjunction with endomysial infiltrates 
in one patient). Rimmed vacuoles, protein aggregation, perifascicular atrophy and perifascicular 
necrosis were not present in any of the reviewed biopsy reports.  
Eight out of 9 patients received treatment with glucocorticoids (88.9%). Seven (7/9, 77.7%) 
received treatment with concomitant immunosuppressants (5/9 methotrexate, 1/9 
cyclosporine, 1/9 methotrexate and cyclosporine). Seven patients (77.8%) responded clinically 
to treatment, two did not have sufficient data available to confirm treatment response. 
 
  
Most patients with PM could be reclassified as another IIM subgroup 
The characteristics of patients who were reclassified as a non-PM IIM subgroup are summarised 
in Tables 1 and 2. CTD-OM patients (7/37, 18.9%) had overlap features (such as Raynaud’s 
phenomenon, sclerodactyly or arthropathy) and CTD-specific autoantibodies (Anti-PM-Scl [n=3], 
anti-U1-RNP [n=1], anti-Ku [n=1]). IMNM was diagnosed based on anti-HMGCR positivity in three 
patients, anti-SRP in one patient, and biopsy results (necrosis and mild inflammation) in one 
patient which was seronegative, fulfilling ENMC proposed criteria for IMNM(5).  
Two patients were reclassified as DM. Both had anti-SAE antibodies, and one of them developed 
a classical DM rash during follow-up (neither of those two cases had skin rash at the initial 
evaluation). CAM was diagnosed in three patients, all seronegative, without skin rash or overlap 
features, all of them with malignancy diagnosed within 3 years of myopathy diagnosis. Non-
inflammatory myopathy (myofibrillar myopathy) was diagnosed in another patient according to 
unresponsiveness to immunosuppressive treatment and muscle biopsy results, although genetic 
confirmation is outstanding. Within the unspecified myositis subgroup (n=6), one patient had a 
suspicion of IBM (not meeting ENMC criteria), one patient had a possible eosinophilic fasciitis 
like-syndrome (proximal weakness and pain, possible cutaneous induration on both forearms, 
high CRP/ESR and myofascial involvement on both biopsy and MRI), one had a HIV associated 
myopathy, two patients were positive for anti-Ro52 without other CTD features, and the last 
patient had an acute syndrome with proximal weakness and high CRP/ESR, without evidence of 
muscle inflammation at the time of review (normal CPK, non-specific biopsy) that responded to 
corticosteroids (possible polymyalgia rheumatica or viral illness). 
There were 6 patients with anti-Ro52. One patient was classified as DM (anti-SAE and anti-Ro52, 
typical skin rash) and three were classified as CTD-OM, presenting with overlap features 
including Raynaud’s or arthritis and positivity for an additional MAA (one patient with anti-Ku, 
one patient with anti-U1-RNP). Only two patients with anti-Ro52 did not have other antibodies 




Despite PM being common in the 255 patients classified by EULAR/ACR criteria in our previous 
study(10), after carefully reviewing each case, only 9/255 (3.5%) retained the diagnosis. These 
patients were carefully reviewed for the presence of features occurring during the additional 
follow-up period suggesting an alternative diagnosis. In addition, some patients were tested for 
the complete MSA/MAA profile by line immunoblot assay in the meantime and their biopsies 
were reviewed. This highlights the importance of careful examination, complete autoantibody 
testing and biopsy analysis when defining IIM subgroup in clinical practice.  Most of our PM cases 
were reclassified as either IMNM or CTD-OM. ASS and IBM were not major subgroups, likely 
because these patients were correctly classified as such in the original cohort(10), nevertheless, 
these subgroups should be considered as a differential diagnosis.  
Anti-Ro52 autoantibodies have been an issue when classifying our cohort. These antibodies are 
associated with various CTDs, including systemic lupus erythematosus, Sjögren’s syndrome, 
systemic sclerosis, inflammatory myopathies and autoimmune hepatitis(13–15). Within IIM  
patients, anti-Ro52 has been described in ASS and DM, often in association with other 
antibodies, with a higher risk for ILD and worse prognosis in some studies(16–18). When 
assessed in patients with anti-U1-RNP antibodies, anti-Ro52 has been associated with higher risk 
for glomerulonephritis and pericarditis(19). It is difficult to classify patients based only on anti-
Ro52 presence as the autoantibody is found in several CTDs. Within IIM, anti-Ro52 is described 
in several subgroups and frequently associated with other MSA or MAA. Only two anti-Ro52 
patients did not present with overlap features or other antibodies.  Despite being tested for the 
complete myositis autoantibody profile, no other MAA or MSA were identified in these patients. 
Given the retrospective design of this study, it is possible that some CTD features were present 
in some of those patients but not reported.  
The widespread use of Bohan and Peter criteria(1,2) has likely resulted in overestimation of the 
relative frequency of PM. Several studies have since reported PM is less frequent than previously 
thought, and even question the existence of the entity altogether(20–23). In a recent study by 
Mariampillai et al(24), 260 patients with IIM were classified into subgroups using multiple 
correspondence and hierarchical clustering analysis. Four clusters were defined, which 
corresponded to IBM, IMNM, DM and ASS. All the previous PM patients were reclassified in to 
one of these four subgroups, adding further evidence to suggest that PM does not represent a 
significant subgroup of IIM patients. 
 
Limitations 
The present study has several limitations. First, due to the retrospective design, data available 
for the cohort is limited in some cases. For example, complete autoantibody testing and biopsy 
results were not available for every patient. Consequently, some of our patients classified as PM 
could still belong to other subgroups, keeping in mind that some clinical features could go 
unnoticed and some antibodies and biopsy reports were not available. Second, the experts 
involved at our centre share similar interpretation of case phenotypes, but this may not be 
representative of IIM experts more generally, nevertheless, all the patients that were diagnosed 
with IBM, IMNM or OM fulfilled published diagnostic/classification criteria. Third, whilst MSA 
and MAA testing using line immunoblot assays has excellent sensitivity and specificity, 
occasional false positives do occur which could contribute to misclassification(25,26). However, 
we carefully reviewed the clinical details of each case in addition to the autoantibody results. 
We therefore did not classify cases using exclusively MSA/MAA data, reducing the chance of 




After carefully reviewing 37 patients previously diagnosed with PM, our study confirms that PM 
can now be regarded as a rare IIM subgroup, with most cases reclassified as alternative disease 
subgroups. IMNM and CTD-OM were the main alternative diagnosis. Those retaining a diagnosis 
of PM were characterized by symmetric muscle weakness, without skin rash or significant CTD 
features, no MSA or MAA, muscle biopsies with HLA-1 upregulation and/or endomysial CD8 
inflammatory infiltrates in most of the patients, and immunosuppressive treatment 
responsiveness. 
Current classification criteria encompass a wide definition of PM, and for the most part such 
patients can now be clinically reclassified in other subgroups. A thorough examination, 
comprehensive autoantibody testing, and careful interpretation of the biopsy results is 
recommended to accurately classify suspected IIM cases. In the future, we think that 
classification criteria should include a stricter definition of PM, including differentiation with 
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